Keyphrases
Glioblastoma
79%
Tumor
36%
Brain Tumor
29%
Overall Survival
24%
Clinical Outcomes
23%
Glioma Surgery
22%
Diagnostic Accuracy
20%
Recurrent Glioblastoma
19%
5-Aminolevulinic Acid (5-ALA)
19%
Intraoperative Magnetic Resonance Imaging (iMRI)
19%
Glioma
18%
Contrast Enhancement
18%
Subarachnoid Hemorrhage
18%
Meningioma
17%
Receptor Targets
16%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
16%
Resection
14%
Craniotomy
14%
Pediatric Brain Tumor
14%
Vasospasm
13%
High-grade Glioma
13%
PET-MRI
12%
Brain Oxygenation
12%
Cerebral Blood Flow
12%
Tyrosine
12%
18F-fluoro-ethyl-tyrosine
11%
Cerebral Vasospasm
11%
Central Nervous System Tumors
11%
Prostacyclin
11%
Epilepsy
11%
Residual Tumor
11%
Bevacizumab Therapy
11%
Population-based
11%
Cerebral Arteriovenous Malformation
11%
Tumor mutational Burden
11%
YKL-40
11%
Positron Emission Tomography
11%
Prognostic Value
11%
18F-fluoroethyl-L-tyrosine (18F-FET)
10%
Copenhagen
9%
Photothermal Therapy
9%
Nivolumab
9%
Hyperlactatemia
9%
Pediatric
9%
IDH mutation
9%
Newly Diagnosed Glioblastoma
8%
Pathophysiology
8%
Neuro-oncological Surgery
8%
Primary Glioblastoma
8%
PET Scan
8%
Medicine and Dentistry
Glioblastoma
100%
Neoplasm
86%
Ganglioglioma
37%
Surgery
35%
Brain Tumor
30%
Magnetic Resonance Imaging
27%
Overall Survival
25%
Fluorine-18
22%
Meningioma
18%
Urokinase Receptor
16%
Pediatrics
16%
Positron Emission Tomography
14%
Aminolevulinic Acid
14%
Diagnostic Accuracy
14%
Bevacizumab
14%
Diagnosis
13%
Positron Emission Tomography - Magnetic Resonance Imaging
12%
Malignant Neoplasm
12%
Pediatric Brain Tumor
12%
Positron Emission Tomography
11%
Pathophysiology
11%
Cohort Analysis
11%
Temozolomide
10%
Craniotomy
10%
Recurrent Disease
9%
Cancer Surgery
9%
Immunotherapy
9%
Retrospective Study
8%
Alpha-Linolenic Acid
7%
Neurosurgery
7%
Xenograft
7%
Gallium 68
7%
Medulloblastoma
7%
Treatment Response
7%
Cancer
6%
Biological Marker
6%
Progression Free Survival
6%
Pediatric Neurology
6%
Cell Survival
6%
Central Nervous System Tumor
6%
Fluorescent Dye
6%
Neurologic Disease
6%
Targeted Therapy
6%
Prospective Study
6%
Pediatrics Patient
6%
Cerebrospinal Fluid
6%
Drive
6%
Central Nervous System
6%
Systematic Review
6%
Observational Study
5%